The Zhitong Finance App learned that Novo Nordisk (NVO.US) announced on Monday that in a late-stage clinical trial, if the test children fully followed the treatment plan, the active ingredient in the major weight loss drug Wegovy, semaglutide (semaglutide), could cause 40.4% of obese children under 6 to 12 years old to no longer be classified as obese after 68 weeks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.